Xencor (XNCR) closed at $29.18 on Oct 26, 2026, up 15.9% on the day. The stock is up 22.6% over the past month, up 46.1% over three months, up 90.6% year to date and up 136.5% over the past year. It trades 13.1% below its 52-week high of $33.58 and 181.3% above its 52-week low of $10.38. The close sits above its 50-day moving average ($25.42) and above its 200-day moving average ($16.64).
Over its last 8 reports the stock moved an average of 3.2% on the first trading day after earnings, beating the options-implied move in 0 of 5.
A 45.5% mitigation rate ignited—is XNCR up 16% in one day enough?
The bispecific antibody data for kidney cancer shows real progress, but the single-dose group sample size is small and revenue relies on one-time payments, so today's increase has already partially overdrawn expectations.
Oct 26, 2026
Over the last 8 reports, XNCR moved an average of 3.2% on the first trading day after earnings. The move beat the options-implied move in 0 of 5 reports.
Yes — the Oct 26, 2026 close of $29.18 is 75.3% above the 200-day average of $16.64.
XNCR closed 13.1% below its 52-week high of $33.58.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
